HR-Positive and Triple-Negative Metastatic Breast Cancer | Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

Featuring perspectives from Prof Peter Schmid and Dr Sara M Tolaney, including the following topics: Introduction: Pharmacology and Sequencing of Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) (0:00) Expanding Role of TROP2-Directed ADCs in mBC Management — Dr Tolaney (21:42) Other Targets for ADC Therapy in mBC — Prof Schmid (44:59) CME information and select publications